Drugs / ERC1671
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05366062 | Jul 2022 → Jul 2025 overdue | malignant glioma | Epitopoietic Research Corporation | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT01903330 | Mar 2014 → Mar 2026 | gliosarcoma | Epitopoietic Research Corporation | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ERC1671 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05366062 ↗ |
| Modality | Vaccine | “prototype clinical vaccine preparation, named Gliovac (or ERC 1671) composed of autologous antigens, derived from the patient's surgically removed tumor tissue, which is...” PMID 25865468 ↗ Apr 2015 |
| Route | Other | “ERC1671/GM-CSF will be intradermally administered” NCT01903330 ↗ |